Absci (ABSI) Liabilities and Shareholders Equity (2020 - 2026)
Absci's (ABSI) quarterly Liabilities and Shareholders Equity came in at $195.6 million in Q1 2026, down 15.85% year-on-year from $232.4 million in Q1 2025, and down 9.57% quarter-over-quarter from $216.3 million in Q4 2025.
Absci (ABSI) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Absci has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $195.6 million for Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $195.6 million, down 15.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $866.8 million (down 7.48% YoY), and the FY2025 annual result was $216.3 million, up 1.26% from the prior year.
- Liabilities and Shareholders Equity came in at $195.6 million for Q1 2026 at Absci, down from $216.3 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $395.5 million in Q1 2022 to a low of $195.6 million in Q1 2026.
- The 5-year median for Liabilities and Shareholders Equity is $245.0 million (2025), against an average of $265.0 million.
- Across the five-year window, Liabilities and Shareholders Equity soared 42.5% in 2022 and sank 32.31% in 2023, its largest moves.
- Absci's Liabilities and Shareholders Equity stood at $321.0 million in 2022, then plunged by 32.31% to $217.3 million in 2023, then slipped by 1.7% to $213.6 million in 2024, then rose by 1.26% to $216.3 million in 2025, then dropped by 9.57% to $195.6 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $195.6 million (Q1 2026), $216.3 million (Q4 2025), and $245.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | Absci | 1.13 Bn | 1.01 Bn | - | 195.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 195.59 Mn |
| Dec 31, 2025 | 216.30 Mn |
| Sep 30, 2025 | 244.99 Mn |
| Jun 30, 2025 | 209.89 Mn |
| Mar 31, 2025 | 232.45 Mn |
| Dec 31, 2024 | 213.61 Mn |
| Sep 30, 2024 | 235.23 Mn |
| Jun 30, 2024 | 255.53 Mn |
| Mar 31, 2024 | 274.90 Mn |
| Dec 31, 2023 | 217.30 Mn |
| Sep 30, 2023 | 236.34 Mn |
| Jun 30, 2023 | 254.15 Mn |
| Mar 31, 2023 | 295.81 Mn |
| Dec 31, 2022 | 321.01 Mn |
| Sep 30, 2022 | 339.39 Mn |
| Jun 30, 2022 | 366.32 Mn |
| Mar 31, 2022 | 395.46 Mn |
| Dec 31, 2021 | 426.20 Mn |
| Sep 30, 2021 | 449.12 Mn |
| Jun 30, 2021 | 257.07 Mn |